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The nerve growth factor (NGF) belongs to a family of proteins termed neurotrophins, consisting of NGF, brain-derived neuro-
trophic factor (BDNF), neurotrophin-3 (NT-3), NT-4/5 and NT-6. Today, NGF is well recognized to mediate a large number of 
trophobiological actions resulting in neurotrophic, immunotrophic and/or metabotrophic effects. The pathobiology of neurode-
generative diseases, including Alzheimer disease, psychiatric disorders (e.g. depression and schizophrenia) and brain parasitic 
infections have in common the effect of altering the brain levels of neurotrophins and in particular NGF. The involvement of 
NGF and its TrkA receptor in these pathologies and the recent promising results of NGF therapies are presented and discussed. 
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INTRODUCTION
At the end of the nineteenth century, it was envisaged by San-
tiago Ramon y Cajal but has not been proven that life at the 
neuronal level requires trophic support. By a rare combination 
Levi-Montalcini, Viktor Hamburger and Stanley Cohen in the 
early 1950’s in the Washington University in St Louis, MO, 
growth factor (NGF), was discovered. This was embodied in 
a conceptual framework of the neurotrophic theory, which 
reveals a pivotal role of effector cells in the control of neuronal 
differentiation, survival and function via production of NGF. 
Today, NGF and its relative molecules collectively designated 
neurotrophins are well recognized as mediators of multiple 
biological phenomena in health and disease, ranging from 
the neurotrophic through immunotrophic to metabotrophic 
effects. Consequently, NGF is implicated in the pathogenesis 
of a large spectrum of neuronal disorders (Alzheimer’s and 
other neurodegenerative diseases) and nonneuronal disorders 
(atherosclerosis, obesity, type 2 diabetes mellitus and other 
cardiometabolic diseases). 
The present review updates and enlarges evidences for 
the involvement of NGF in both pathogenesis and therapy of 
various brain diseases (Tabl. 1).
Table 1. Potential role of nerve growth factor in the patho-
genesis and therapy of brain diseases
Neurological diseases
Alzheimer’s disease, Mild cognitive impairment, Huntington’s disease, 
Parkinson’s disease, 
Parasitic infections, Human immunodeficiency virus-associated demen-
tia, Epilepsy, Down syndrome, Rett syndrome 
Psychiatric diseases 
Depression, Schizophrenia, Eating disorders (anorexia nervosa; bulimia 
nervosa), Autism, 
Attention deficit and hyperactivity disorder (ADHD)
NERVE GROWTH FACTOR
neuropeptide that regulates the proliferation and survival 
of target neurons (1). Nerve growth factor plays a subtle 
role in several brain pathologies leading to brain cell death 
and/or neurodegeneration during development or during 
aging (2–11). Nerve growth factor is synthesized as a 130 
kD precursor (proNGF) that is a complex of three proteins: 
-NGF, -NGF and -NGF the latter acting as a serine pro-
tease that cuts the Beta subunit N terminal producing the 26 
kD mature NGF that is biologically active as a multifunc-
tional signaling molecule (12–14). Nerve growth factor is 
involved primarily in the growth, survival, and proliferation 
of sympathetic and sensory neurons that undergo apopto-
sis in its absence (15–18). It also plays a delicate role in 
the physiological regulation of other biological structures 
as the immune and the endocrine systems and the adipose 
tissue (14,19–23). Nerve growth factor binds two classes of 
receptors: the tropomyosin-related kinase A (TrkA), and the 
NTR) (12, 24, 
25). TrkA receptor binding produces the homodimerization 
of the receptor and the autophosphorylation of the tyrosine 
residue of the cytoplasmic tail. This site of TrkA phospho-
rylation is a docking site for the Shc adaptor protein that is 
in turn phosphorylated starting several intracellular path-
ways involved in cell survival (12, 26). Among them, one 
involves the activation of the serine/threonine kinase Akt 
and develops with the recruitment on TrkA receptor com-
plex of a second adaptor protein, the growth factor receptor 
bound protein 2 (Grb2) and another docking protein, the 
Grb2-associated Binder1 (GAB1). This complex activates 
phosphatidylinositol-3 kinase (Pl3K), that activates Akt. 
Blocking the activity of Pl3K or Akt provokes the death 
of sympathetic neurons in culture also in presence of NGF 
administration, while when both kinases are constitutively 
expressed neurons can survive without NGF (27,28).  
Another pathway of NGF mediated neuronal survival in-
volves the mitogen-activated protein kinase (MAPK). This 
pathway leads to activation of the membrane-associated G 
protein Ras that phosphorylates the serine/threonine kinase 
Raf. This phosphorylation activates the MAPK cascade that 
regulates transcription (26). Both of these pathways give rise 
to phosphorylation of the cyclic AMP response element bind-
ing protein (CREB), a transcription factor that translocates 
into the nucleus, where controls the expression of antiapop-
totic genes. 
NGF and Alzheimer disease
Alzheimer disease (AD), the most common form of demen-
tia in the old age, is characterized by early perturbations of 
synaptic proteins and synaptic functions with the generation 
of abnormal tau and amyloid proteins. After the release in 
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the intracellular space of these abnormal proteins begins the 
massive deposition of senile plaques (SP) of -amyloid (A ) 
that originate from hyperphosphorylated tau protein. As a 
consequence, during the progression of the disease, appears a 
loss and a complete deterioration of the brain homeostasis 
(29–32). The basal forebrain cholinergic neurons innervate 
the hippocampus and the cerebral cortex, the regions that 
control memory and attention. These regions are more sus-
In the pathophysiological mechanisms of AD, it turned out 
to be fundamental the protective role of neurotrophic factors, 
secreted proteins that control differentiation, plasticity, prun-
ing and survival of forebrain cholinergic neurons (FBCN) of 
the hypothalamus, cortex and hippocampus. Indeed, the sign-
aling of these peptides is seriously altered in the course of the 
disease (37). Among these neurotrophins the most studied for 
its role in the AD is NGF, a glycoprotein of three subunits 
,  and  that is produced as a precursor pro-NGF and is 
processed intracellularly to mature NGF by the subunit of the 
protein (37, 38).
Nerve growth factor signaling involves three types of re-
-
tor (p75NTR) and sortilin. NGF binding to its receptor TrkA 
activates the pathway signaling of cell survival, while in the 
presence of lower levels of NGF and/or TrkA the precursor 
form of NGF (pro-NGF) binds to p75NTR and to sortilin pro-
voking an apoptotic signaling that brings to neurodegenera-
tion (39–41).
Nerve growth factor release by cortical and hippocampal 
neurons is involved in the processing of amyloid precursor 
protein (APP) to generate the soluble APP that is neuropro-
tective and a strong inhibitor of the enzyme -secretase 1 
(BACE1) that controls APP amyloidogenic cleavage (42, 
43). Recent studies in animal and cellular models have 
shown the protective role of NGF against AD induced neuro-
degeneration. Also, there is evidence that the perturbation of 
NGF signaling is one of the earliest events in AD onset (44). 
In a cellular model such as primary hippocampal neurons, 
the NGF deprivation generates an Alzheimer’s like molecu-
lar syndrome with the development of A -amyloid plaques 
-
tibody directed to NGF provokes similar phenotypic effects 
The protective role of NGF observed in vivo and in vitro is 
exerted by the modulation of the processing of amyloid pre-
cursor protein (APP) (42, 43).
Nerve growth factor stimulation of primary choliner-
gic septal neurons promotes the binding of NGF receptor 
TrkA to APP. This binding blocks the APP phosphorylation 
at threonine 668 (T668) residue in the cytosolic tail of the 
protein. T668 phosphorylation is a post-translational modi-
BACE1, that controls the amyloidogenic pathway of matura-
tion (42,43,46).  
-
loid generation increases and could affect the initial synaptic 
alteration observed in mild cognitive impairments and early 
AD. The newly generated amyloid inhibits the endocytosis of 
NGF/TrkA complex and this negative feedback loop marks 
the AD onset (29). 
In rat models of aging, elevated levels of pro-NGF and 
p75NTR in hippocampus and prefrontal cortex are associated 
-
crease in pro-NGF levelss was also observed in mild cogni-
tive impairment and AD patients and also in postmortem AD 
brain examination (44). The perturbation of NGF signaling is 
an early event during the progression of the AD as evidenced 
by the studies on animal and cellular models (30). In ani-
mal models of aged rats the blocking of NGF/TrkA signaling 
animal models of AD, the alteration of NGF signaling brings 
to a general loss of central cholinergic function (50). The ef-
fect of the imbalance in NGF/TrkA signaling is a pathologi-
cal APP processing (45). In transgenic mice lacking the APP/
TrkA interaction, it is observed a serious degeneration of 
seem to support the hypothesis of the neurotrophic model of 
AD development where the reduction of NGF level and the 
increase of pro-NGF would trigger the synaptic failure and 
the abnormal amyloid and tau deposition starting a neurode-
generative cascade (28,52).
New pieces of evidence prove that the relationship be-
tween NGF and APP processing relies on a physical inter-
action between APP and NGF receptors (30). The APP jux-
ta-membrane region which contains the  and -secretase 
 peptide is 
p75NTR (53). APP and TrkA proteins localize in the plasma 
membrane, endoplasmic reticulum (ER), Golgi and endocyt-
4
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ic vesicles where the proteins form homodimers (30).
In primary septal neurons, NGF treatment increases APP/
TrkA complexes in ER and Golgi without increasing the 
protein level probably because NGF affects the association 
through the control of APP phosphorylation (30, 43). NGF 
withdrawal induces a decrease of APP/TrkA complexes and 
the same pattern is observed with cell death inducers such 
as A  peptide, and rapamycin. Furthermore, NGF, favoring 
APP/TrkA complexes, disadvantages the APP/APP homodi-
mers that are more prone to amyloidogenic processing car-
ried out by  and -secretase (30, 43).  
the physiological or amyloidogenic pathway (54).  The phos-
phorylation of threonine residue 668 (T668) is connected to 
This phosphorylation blocks APP/TrkA binding and increas-
es A  production in cholinergic neurons in vivo and in vitro. 
level in cultured BFCN. It is possible that the detachment of 
APP from TrkA is caused by a change in the conformation of 
APP upon this phosphorylation (43).
In the physiological anti-amyloidogenic pathway, bind-
ing of NGF to TrkA induces TrkA phosphorylation and TrkA 
docking of the signaling adaptor SH2 containing sequence 
C (ShcC). Activated ShcC blocks c-Jun N-terminal kinase 
(JNK), a ser/thr APP kinase, preventing the APP phosphoryl-
ation at threonine residue 668 (T668). Since TrkA can bind 
only APP molecules not phosphorylated at T668, the NGF 
reduction of APP p668 levels stimulates ATP-TrkA bind-
membrane and Golgi apparatus and the preferential cleav-
age of APP by the neuronal -secretases ADAM10-17. Con-
versely, reduced availability of mature NGF and/or reduced 
expression levels of TrkA result in pre-apoptotic signals that 
activate  JNK, increase APP pT668 and disturb APP-TrkA 
interaction favoring the Secretase 1 amyloidogenic path-
way (43).
out downregulating T668 phosphorylation, stimulating APP/
Golgi complex, that is depleted of the amyloidogenic enzyme 
like BACE1. Tau pathology is implicated in non-Alzheimer 
disease pathophysiology (suspected non-Alzheimer disease 
pathophysiology - SNAP). In AD many studies demonstrated 
a synergism between tangles and plaques, with abnormal tau 
that enhances A  toxicity and vice-versa (57, 58).
Nerve growth factor can regulate the steady-state levels 
and the posttranslational maturation of tau that is phosphoryl-
ation, cleavage, and ubiquitination (59, 60). NGF withdrawal 
brings to hyperphosphorylation of tau that is A -dependent 
and to abnormal cleavage of the N terminal fragment of the 
protein that lacks the microtubule-binding domain. The same 
tau fragment was also observed in animal AD models with 
impaired NGF signaling (59, 61).
NGF and Schizophrenia
Growth factors that control pathways involved in normal 
brain development have an important role in the pathophysi-
ology of mental illness that has also a neurodevelopmental 
in patients and also in animal models where altered levels of 
these proteins induce psychiatric behavior (62).
During the embryonic and postnatal stages, psychophysi-
cal stress altering the environment can modify the normal 
development of the brain opening the way in the adulthood to 
psychopathologies such as hyper-anxiety, anomalous social 
behavior, alcohol abuse and drug dependence, schizophrenia, 
and depression (63–67). In the rat, gestational stress increas-
es maternal and fetal plasma corticosterone with dysregula-
tion of the hypothalamic–pituitary–adrenal (HPA) axis and 
a prolonged elevation of plasma glucocorticoids in response 
to stress events (64, 65). Synaptic development and neuro-
-
ticosterone and corticotrophin-releasing hormone (CRH) in 
developing brain causing behavioral dysfunctions in adult-
hood. For example, rats exposed to intrauterine stress de-
velop depressive-like behaviors and hyper-anxiety coupled 
with the increase of CRH activity in the amygdala (64,65). 
Interestingly, abnormalities in the HPA axis described in pre-
natally stressed animals were also reported in humans with 
endogenous depression (68–70). Also during early postnatal 
life, the development of the nervous system is sensitive to 
stress events, and this contributes to inter-individual differ-
ences in vulnerability to psychopathology. In the postnatal 
development of CNS, the neural network undergoes deep 
rearrangements (71, 72) and is particularly sensitive to ex-
ternal stimuli. In this phase, the role of NGF and BDNF is 
to modulate brain plasticity to better adapt to the environ-
ment. As an example, mice grown in a nest with caregiving 
mothers display better social interaction and skills compared 
to mice bred in standard laboratory conditions. The socially 
enriched mice present also higher levels of NGF and BDNF 
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in hippocampus and hypothalamus (73, 74). In the mouse, 
NGF is produced and secreted by the submaxillary salivary 
glands (75, 76). Neurobehavioral studies have shown that in-
release of NGF from salivary glands into the bloodstream. 
These observations demonstrated a correlation between the 
serum concentration of NGF and the status achieved in the 
levels of NGF compared to dominant mice (77–79). Other 
NGF levels and subordinate behavior (80, 81). In male mice, 
the chronic administration of NGF reduced aggressive be-
havior (79). NGF release was activated by psychosocial 
-
cal stressors have less pronounced effects (73, 74). Intermale 
aggressive behavior increases the synthesis of NGF in the 
hypothalamus (82) probably because the NGF levels respond 
to psychological stimuli connected to fear and anxiety and 
interplay with hormones and neurotransmitters to integrate 
the neuroendocrine response and the behavior to ensure  the 
physiological homeostasis (2, 14, 81). Data from humans and 
animal models suggest a role of neurotrophins also in vulner-
ability to stress-related neuropsychosis (83, 84). Growing lit-
erature evidences showed that in psychopathological disease 
the constitutive levels of neurotrophins are altered in both 
brain and plasma. In schizophrenic patients, without neuro-
leptic therapy, the plasma levels of NGF are lower compared 
to healthy controls (85). Administration of the antipsychotic 
drug haloperidol in human and mice drastically reduces the 
plasma levels of NGF (86) inducing sedation. In contrast, 
the atypical antipsychotics risperidone, clozapine, and olan-
zapine showed higher levels of plasmatic NGF compared to 
critical role of NGF during the development of cholinergic 
neurons that control learning and memory could explain the 
-
cits observed in this disease because the low levels of NGF 
schizophrenic patients, brain imaging studies showed altera-
tion in brain areas such as prefrontal, temporal and anterior 
cingulum known to be involved in affective-cognitive inte-
gration (89). Also, the schizophrenic brain post-mortem ex-
amination showed a reduction of cell proliferation in the en-
torhinal cortex, anterior cingulate and prefrontal region that 
could explain the origin of the disease (85, 89). In animal 
symptoms (90) develop also by maternal exposure to risk 
factors such as ethanol and drug abuse that inhibit entorhinal 
and cortical neurogenesis (91).
Schizophrenia is a multifactorial mental disease triggered 
by social, genetic and developmental factors (92). Among the 
genes that have been observed to be involved in this disease 
one is Disrupted-in-schizophrenia 1 (DISC1) (93,94) which 
is expressed by neurons of the cerebral cortex, hippocampus, 
olfactory bulb and cerebellum in rat brain (95–97). The protein 
binds other proteins including fasciculation and elongation 
protein zeta-1(Fez1), involved in axonal outgrowth. DISC1-
Fez1 molecular complex colocalizes in the growth cone of 
neurite suggesting a role in the process of extension also con-
ontogenic stages. Studying the neurodifferentiation of PC12 
cells stimulated with NGF was observed a drastic increase of 
Fez1 suggesting that NGF controls the neurite extension and 
outgrowth upregulating DISC1-Fez1 complex (92). When the 
DISC1 translocation prevents the complex being formed, neu-
rite extension cannot happen and the brain development re-
mains immature, supporting the hypothesis that schizophrenia 
is essentially a neurodevelopmental disease (92).
NGF and Major Depression Disorder
Major depression disorder (MDD) is the most common of 
brain disorders and involves depression, scarce interest in 
normal daily activities, fatigue, a decrease in concentra-
tion, suicidal intentions (98). Several neurotrophins includ-
ing NGF and BDNF are involved in MDD pathogenesis (99, 
100). Major depression disorder patients present reduced 
serum NGF, and the same reduction was observed in hip-
pocampus mRNA and protein expression of NGF, BDNF and 
their receptors in post-mortem examination (101, 102).  The 
chemical mediator of NGF reduction is interferon-gamma 
(IFN- ), as was observed in IFN-  knockout mice models 
that develop a depressive-like behavior, an increased immo-
bility and a parallel reduction of NGF levels (103, 104).
The administration of NGF in rats decreases the expres-
sion of cholinergic gene CHRNA5 and prokineticin recep-
-
triptyline therapy. The improvement of the depression-like 
behavior is realized by modifying the expression of several 
genes of amygdala and hippocampus (105).
NGF in Autism Spectrum Disorder
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communication and repetitive pattern of behavior. Genetic 
aberrations play a crucial role in developing ASD with hun-
dreds of genes associated with it, which however do not show 
to converge in a common molecular pathway. Genetic studies 
and behavioral observations demonstrate the overlapping of 
ASD with other psychiatric disorders, such as schizophre-
Disorder (ADHD) (106, 107). In a study of differential alter-
native splicing (DAS) in the blood of 2-4 years old boys with 
in several genes of NGF receptors and signaling compared 
to controls (108). Another study of Lu et al showed several 
-
tion that is one of the autistic trail (109).  
NGF and Alcohol-Induced Mental Retardation
Several human evidences have shown that chronic or binge 
alcohol consumption as well as alcohol exposure during devel-
opment are a main inducing-cause of brain changes (110) and 
mental retardation in both adults and children (88, 111–119). As 
for the gestational alcohol consumption, the plethora of effects 
in children induced by ethanol are described as Fetal Alcohol 
Spectrum Disorders (120–123). It has also been clearly dem-
onstrated that chronic or binge alcohol consumption as well as 
alcohol exposure during development may impair brain neuro-
trophic factors production and the expression of their receptors 
(124–132). NGF is one of the most important neurotrophins 
involved in ethanol-induced toxicity. Indeed, NGF and their 
receptors are known to be altered in the brain during prenatal/
acute/chronic alcohol consumption (133–138). In particular, 
as previously indicated (133) alcohol inhibits the expression 
of endogenous extracellular signal-regulated kinase (ERK) 
and the phosphatidylinositol-3-kinase (PI3K) (139–141). In 
addition, data disclosed several epigenetic rules of NGF and 
BDNF, the serum levels of interleukin-6 (IL-6) and tumor 
-
hol dependence (142, 143). In particular, it has been shown 
an increase in NGF and IL-6 serum levels following alcohol 
serum levels and the history of alcohol consumption, suggest-
ing that changes in the methylation of neurotrophins genes 
may contribute to the development of alcohol dependence by 
affecting relevant downstream signalling cascades (133, 143). 
NGF and Brain Parasitosis
The role of NGF in parasitic disease is not yet clear estab-
lished but some clues have emerged from the study on Trypa-
nosoma cruzi and Schistosoma mansoni
of the brain.
Chagas disease or American trypanosomiasis is a tropi-
cal parasitic disease caused by the protist Trypanosoma cruzi 
spread to humans and mammals by the insects “kissing bugs” 
of the subfamily Triatominae (144, 145). During the early 
stage, symptoms are not present or are mild with fever, head-
ache, swollen lymph nodes. Only 40% of people develop se-
vere symptoms of the disease after 30-40 years from the in-
fection that include heart failure due to enlargement of heart 
ventricles, or enlarged esophagus or colon (megaesophagus 
or megacolon). This disease affects 6,6 million people mostly 
in Central America and Mexico (146).  
Trypanosoma cruzi produces the NGF mimetic neurotro-
phin called parasite-derived neurotrophic factor (PDNF), a 
membrane-bound neuraminidase/trans-sialidase that can 
bind TrkA but not p75NTR (147, 148).
Trypanosoma infection of CNS is usually asymptomatic 
and neuronal examination has shown neuroprotection and 
parasite nest (149). Neuroprotection and neuroregeneration 
were also observed in animals with acute or chronic infection 
(150–153). Signs of sprouting of sympathetic and parasym-
increased levels of neurotransmitters (154, 155). These data 
have shown that PDNF is a functional mimic of NGF that can 
bind TrkA in an NGF inhibitable manner, can induce TrkA 
autophosphorylation and can trigger Pl3K/Akt and MAPK-
Erk1/2 signaling that promotes cell survival and neurite 
outgrowth. The inability of binding p75NTR inhibits the cell-
death signaling pathway (156, 157). Given the critical role of 
TrkA in neuronal maintenance, the parasitic invader utilizes 
this receptor to reduce tissue damage, to stimulate protec-
tive mechanisms and tissue repair maximizing host-parasite 
equilibrium in order to prolong parasitism. This mechanism 
interaction (156).
Neuroschistosomiasis (NS) refers to the Schistosoma man-
soni infection of the central nervous system and depends ba-
sically on the presence of parasite eggs in the nervous tissue 
and on the host immune response. After eggs deposition, the 
mature embryo secretes and excretes antigenic and immuno-
genic mediators that start the granulomatosis reaction. A large 
number of eggs and granulomas in CNS regions damage the 
-
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fect (158–162). In infected mice that manifest granulomas in 
several CNS regions it is observed an increase in NGF levels 
in the cortex, hypothalamus, and brain stem with paw hyperal-
gesia (163,164). This murine model of chronic infection sug-
in human infection are associated with abnormal NGF levels 
and/or activity in peripheral and central nervous system caused 
by the local formation of granulomas (75,165–171).
NGF-based Therapy
The protective effect of NGF in animal models of neurode-
generative disease has led to clinical trials of NGF therapy 
in humans for several brain diseases including AD, schizo-
phrenia (172,173) and hopefully for other brain pathologies.
Encouraging results were observed in patients’ basal fore-
brain in which were implanted connective cells engineered 
to synthesize and secrete NGF. In these experiments were 
-
ers. Also, the cell showing signs of pathology and protein 
clumps inside the cell body maintained a healthy size, ac-
tivated prosurvival signaling and manifested stress resist-
that contain the NGF gene were directly injected in the basal 
forebrain (174, 175). The protective role of NGF and its pro-
gressive decrease in AD is the rationale of NGF therapy in 
which the administration of exogenous NGF could antago-
-
ing results were obtained in rodents where intracerebral NGF 
delivery was neuroprotective for cholinergic neurons. Also in 
AD models like APP/PSI transgenic mouse, the less invasive 
ocular or nasal administration of NGF reduces beta-amyloid 
deposition (176). In AD patients NGF gene therapy in phase I 
has shown axonal sprouting without side effects (176).
Anomalies in the levels of NGF or NGF signaling and the 
resulting impairment of neuroplasticity and cognitive func-
tions were also observed in psychiatric disorders such as 
schizophrenia, depression, bipolar disorders, alcohol use dis-
orders and autism. In schizophrenic patients in therapy with 
atypical antipsychotic drugs, NGF levels increase leading to 
a reduction of negative symptoms (49, 177). In bipolar disor-
ders, NGF decreases during the manic state and is rescued by 
lithium administration that increases the NGF concentration 
in the frontal cortex, hippocampus, and amygdala (178). In 
children with Rett syndrome, a condition that causes a delay 
in development and cognitive disability resembling autism, 
therapies with NGF-like activity drugs improve motor and 
cortical functions and increase social interactions (179).
CONCLUSIONS
Many years of research have well documented the impor-
tant trophic and homeostatic role of NGF that exerts its 
modulatory activities on nervous, endocrine, adipose and im-
mune system functions. Future researches, through a greater 
knowledge of the mechanism of action of this small and ver-
satile peptide, will help to develop updated brain therapeutic 
strategies for many clinical areas including those involving 
-
nology  (2, 20, 23, 180, 181).  
CONFLICT OF INTEREST STATEMENT
-
the subject matter discussed in this review article.
ACKNOWLEDGEMENTS
We apologize to the authors of many relevant articles that 
were not quoted here for reasons of brevity.
REFERENCES
1. Levi-Montalcini R. The nerve growth factor 35 years 
later. Science 1987; 237:1154–1162. DOI:10.1126/sci-
ence.3306916
2. Yanev, Stanislav, Aloe L, Fiore M, Chaldakov GN. Neu-
rotrophic and metabotrophic potential of nerve growth 
factor and brain-derived neurotrophic factor: Linking 
cardiometabolic and neuropsychiatric diseases. World J 
Pharmacol 2013; 2:92. DOI:10.5497/wjp.v2.i4.92
3. Greco A, Ralli M, De Virgilio A, Inghilleri M, Fusconi 
M, de Vincentiis M. Letter to the Editor: Autoimmune 
pathogenic mechanisms in Huntington’s disease. Au-
toimmun Rev 2018; 17:942–943. DOI:10.1016/j.au-
trev.2018.04.003
4. Hillis J, O’Dwyer M, Gorman AM. Neurotrophins and 
B-cell malignancies. Cell Mol Life Sci 2016; 73:41–56. 
DOI:10.1007/s00018-015-2046-4
5. Skaper SD. Nerve growth factor: a neuroimmune 
crosstalk mediator for all seasons. Immunology 2017; 
151:1–15. DOI:10.1111/imm.12717
6. Pepeu G, Grazia Giovannini M. The fate of the brain 
cholinergic neurons in neurodegenerative diseases. 
Brain Res 2017; 1670:173–184. DOI:10.1016/j.brain-
res.2017.06.023
8
Biomed Rev 29, 2018
Ciafrè et al
7. Aygun N. Biological and genetic features of neuroblas-
toma and their clinical importance. Curr Pediatr Rev 
2018; 14:73–90. DOI:10.2174/1573396314666180129
101627
8. Fields J, Dumaop W, Langford TD, Rockenstein E, Ma-
sliah E. Role of neurotrophic factor alterations in the neu-
rodegenerative process in HIV associated neurocognitive 
disorders. J Neuroimmune Pharmacol 2014; 9:102–116. 
DOI:10.1007/s11481-013-9520-2
9. Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel 
NK. GDNF, NGF and BDNF as therapeutic options for 
neurodegeneration. Pharmacol Ther 2013; 138:155–175. 
DOI:10.1016/j.pharmthera.2013.01.004
10. Iulita MF, Caraci F, Cuello AC. A link between nerve 
growth factor metabolic deregulation and amyloid-beta-
CNS Neurol 
Disord Drug Targets 2016; 15:434–447.
11. Greco A, Ralli M, Inghilleri M, De Virgilio A, Gallo 
A, de Vincentiis M. Letter to the Editor: Autoimmune 
pathogenic mechanisms in amyotrophic lateral sclero-
sis. Autoimmun Rev 2018; 17:530–531. DOI:10.1016/j.
autrev.2018.04.003
12. Kaplan DR, Martin-Zanca D, Parada LF. Tyrosine 
phosphorylation and tyrosine kinase activity of the trk 
proto-oncogene product induced by NGF. Nature 1991; 
350:158–160. DOI:10.1038/350158a0
13. Donovan MJ, Miranda RC, Kraemer R, McCaffrey 
TA, Tessarollo L, Mahadeo D, et al. Neurotrophin and 
neurotrophin receptors in vascular smooth muscle cells. 
Regulation of expression in response to injury. Am J 
Pathol 1995; 147:309–324. 
14. Fiore M, Chaldakov GN, Aloe L. Nerve growth factor 
as a signaling molecule for nerve cells and also for the 
neuroendocrine-immune systems. Rev Neurosci 2009; 
20:133–145. DOI:10.1515/REVNEURO.2009.20.2.133
15. Carito V, Venditti A, Bianco A, Ceccanti M, Serrilli AM, 
Chaldakov G, et al. Effects of olive leaf polyphenols on 
male mouse brain NGF, BDNF and their receptors TrkA, 
TrkB and p75. Nat Prod Res 2014; 28:1970–1984. DOI
:10.1080/14786419.2014.918977
16. De Nicoló S, Tarani L, Ceccanti M, Maldini M, Natella F, 
Vania A, et al. Effects of olive polyphenols administration 
on nerve growth factor and brain-derived neurotrophic 
factor in the mouse brain. Nutrition 2013; 29:681–687. 
DOI:10.1016/j.nut.2012.11.007
17. van der Laan BF, Freeman JL, Asa SL. Expression of 
growth factors and growth factor receptors in normal 
and tumorous human thyroid tissues. Thyroid 1995; 
5:67–73. 
18. Freeman RS, Burch RL, Crowder RJ, Lomb DJ, Schoell 
MC, Straub JA, et al. NGF deprivation-induced gene 
expression: after ten years, where do we stand? Prog 
Brain Res 2004; 146:111–126. DOI:10.1016/S0079-
6123(03)46008-1
19. Chaldakov GN, Beltowsky J, Ghenev PI, Fiore M, 
 et al. Adipoparacrinology 
– vascular periadventitial adipose tissue (tunica adi-
posa) as an example. Cell Biol Int 2012; 36:327–330. 
DOI:10.1029/2011JD017014
20. Chaldakov GN, Fiore M, Tonchev AB, Dimitrov 
D, Pancheva R, Rancic G, et al. Homo obesus: A 
nutrition insight. Curr Pharm Des 2007; 13:2176–2179. 
DOI:10.2174/138161207781039616
21. Chaldakov GN, Fiore M, Ghenev PI, Stankulov IS, Aloe 
L. Atherosclerotic lesions: Possible interactive involve-
ment of intima, adventitia and associated adipose tissue. 
Int Med J 2000; 7:43–49. 
22. Tore F, Tonchev A, Fiore M, Tuncel N, Atanassova 
P, Aloe L, et al. From adipose tissue protein secre-
tion to adipopharmacology of disease. Immunol 
Endocr Metab Agents Med Chem 2007; 7:149–155. 
DOI:10.2174/187152207780363712
23. Chaldakov GN, Fiore M, Tonchev AB, Aloe L. Neu-
roadipology: A novel component of neuroendocrinol-
ogy. Cell Biol Int 2010; 34:1051–1053. DOI:10.1042/
CBI20100509
24. Levi-Montalcini R. The nerve growth factor: 35 years 
later (Nobel Lecture). Angew Chemie Int Ed English 
1987; 26:707–716. DOI:10.1002/anie.198707073
25. Chao M V. Trophic factors: An evolutionary cul-de-sac 
or door into higher neuronal function? J Neurosci Res 
2000; 59:353–355.
26. Sanes DH, Reh TA, Harris WA. Development of the nerv-
ous system. Elsevier 2005.
27. Yano H, Chao M V. Neurotrophin receptor structure 
and interactions. Pharm Acta Helv 2000; 74:253–260. 
DOI:10.1016/S0031-6865(99)00036-9
28. Niewiadomska G, Mietelska-Porowska A, Mazurkiewicz 
M. The cholinergic system, nerve growth factor and the 
cytoskeleton. Behav Brain Res 2011); 221:515–526. 
DOI:10.1016/j.bbr.2010.02.024
9
Biomed Rev 29, 2018
Nerve growth factor in brain diseases 
29. Xu C-J, Wang J-L, Jin W-L. The Emerging Therapeutic 
Role of NGF in Alzheimer’s Disease. Neurochem Res 
2016; 41:1211–1218. DOI:10.1007/s11064-016-1829-9
30. Canu N, Amadoro G, Triaca V, Latina V, Sposato V, 
Corsetti V, et al. The Intersection of NGF/TrkA Signaling 
and Amyloid Precursor Protein Processing in Alzhei-
mer’s Disease Neuropathology. Int J Mol Sci 2017; 18: 
DOI:10.3390/ijms18061319
31. Angelucci F, Gelfo F, Fiore M, Croce N, Mathé AA, 
Bernardini S, et al. The effect of neuropeptide Y on cell 
survival and neurotrophin expression in in-vitro models 
of Alzheimer’s disease. Can J Physiol Pharmacol 2014; 
92:621–630. DOI:10.1139/cjpp-2014-0099
32. Scott SA, Mufson EJ, Weingartner JA, Skau KA, Crutcher 
KA. Nerve growth factor in Alzheimer’s disease: in-
creased levels throughout the brain coupled with declines 
in nucleus basalis. J Neurosci 1995; 15:6213–21.
33. Arendt T. Impairment in memory function and neuro-
degenerative changes in the cholinergic basal forebrain 
system induced by chronic intake of ethanol. Cell 
Anim Model Aging Dement Res 1994; 44:173–187. 
DOI:10.1007/978-3-7091-9350-1_13
34. Arendt T, Bruckner MK, Bigl V, Marcova L. Dendritic 
reorganisation in the basal forebrain under degenerative 
conditions and its defects in Alzheimer’s disease. III. 
The basal forebrain compared with other subcortical 
areas. J Comp Neurol 1995; 351:223–246. DOI:10.1002/
cne.903510204
35. Arendt T, Marcova L, Bigl V, Bruckner MK. Dendritic 
reorganisation in the basal forebrain under degenera-
tive conditions and its defects in Alzheimer’s disease. I. 
Dendritic organisation of the normal human basal fore-
brain. J Comp Neurol 1995; 351:169–188. DOI:10.1002/
cne.903510202
36. Arendt T, Bruckner MK, Bigl V, Marcova L. Dendritic 
reorganisation in the basal forebrain under degenerative 
conditions and its defects in Alzheimer’s disease. II. 
Ageing, Korsakoff’s disease, Parkinson’s disease, and 
Alzheimer’s disease. J Comp Neurol 1995; 351:189–222. 
DOI:10.1002/cne.903510203
37. Skaper SD. Neurotrophic factors: An overview. Methods 
Mol Biol 2018; 1727:1–17. DOI:10.1007/978-1-4939-
7571-6_1
38. Budni J, Bellettini-Santos T, Mina F, Garcez ML, Zugno 
AI. The involvement of BDNF, NGF and GDNF in aging 
and Alzheimer’s disease. Aging Dis 2015; 6:331–341. 
DOI:10.14336/AD.2015.0825
39. Huang EJ, Reichardt LF. Trk receptors: Roles in neuronal 
signal transduction. Annu Rev Biochem 2003; 72:609–
642. DOI:10.1146/annurev.biochem.72.121801.161629
40. Guerios SD, Wang Z-Y, Boldon K, Bushman W, Bjorling 
DE. Blockade of NGF and trk receptors inhibits increased 
peripheral mechanical sensitivity accompanying cystitis 
in rats. AJP Regul Integr Comp Physiol 2008; 295:R111–
R122. DOI:10.1152/ajpregu.00728.2007
41. Chao M V., Hempstead BL. p75 and Trk: A two-
receptor system. Trends Neurosci 1995; 18:321–326. 
DOI:10.1016/0166-2236(95)93922-K
42. Triaca V. Homage to Rita Levi-Montalcini. Molecular 
mechanisms of Alzheimer’s disease: NGF modula-
tion of APP processing. Adipobiology 2013; 5:7–18. 
DOI:10.14748/adipo.v5.292
43. Triaca V, Sposato V, Bolasco G, Ciotti MT, Pelicci P, 
Bruni AC, et al. NGF controls APP cleavage by down-
regulating APP phosphorylation at Thr668: relevance 
for Alzheimer’s disease. Aging Cell 2016; 15:661–672. 
DOI:10.1111/acel.12473
44. Mufson EJ, He B, Nadeem M, Perez SE, Counts SE, 
Leurgans S, et al. Hippocampal proNGF signaling 
pathways and beta-amyloid levels in mild cognitive 
impairment and Alzheimer disease. J Neuropathol 
Exp Neurol 2012; 71:1018–1029. DOI:10.1097/
NEN.0b013e318272caab
45. Calissano P, Matrone C, Amadoro G. Nerve growth factor 
as a paradigm of neurotrophins related to Alzheimer’s 
disease. Dev Neurobiol 2010; 70:372–383. DOI:10.1002/
dneu.20759
46. Ruberti F, Capsoni S, Comparini A, Di Daniel E, Franzot 
et al. Phenotypic knockout of nerve growth 
in basal forebrain cholinergic neurons, cell death in the 
spleen, and skeletal muscle dystrophy. J Neurosci 2000; 
20:2589–2601.
47. Terry AVJ, Kutiyanawalla A, Pillai A. Age-dependent 
alterations in nerve growth factor (NGF)-related 
proteins, sortilin, and learning and memory in rats. 
Physiol Behav 2011; 102:149–157. DOI:10.1016/j.
physbeh.2010.11.005
48. Yegla B, Parikh V. Effects of sustained proNGF blockade 
on attentional capacities in aged rats with  compromised 
cholinergic system. Neuroscience 2014; 261:118–132. 
DOI:10.1016/j.neuroscience.2013.12.042
10
Biomed Rev 29, 2018
Ciafrè et al
49. Parikh V, Howe WM, Welchko RM, Naughton SX, 
D’Amore DE, Han DH, et al. Diminished trkA receptor 
signaling reveals cholinergic-attentional vulnerability  of 
aging. Eur J Neurosci 2013; 37:278–293. DOI:10.1111/
ejn.12090
50. Counts SE, Mufson EJ. The role of nerve growth factor 
receptors in cholinergic basal forebrain degeneration in 
prodromal Alzheimer disease. J Neuropathol Exp Neurol 
2005; 64:263–272.
51. Matrone C, Di Luzio A, Meli G, D’Aguanno S, Severini 
C, Ciotti MT, et al. Activation of the amyloidogenic route 
by NGF deprivation induces apoptotic death  in PC12 
cells. J Alzheimers Dis 2008; 13:81–96.
52. Latina V, Caioli S, Zona C, Ciotti MT, Amadoro G, Calis-
sano P. Impaired NGF/TrkA signaling causes early AD-
linked presynaptic dysfunction in cholinergic primary 
neurons. Front Cell Neurosci 2017; 11:68. DOI:10.3389/
fncel.2017.00068
53. O’Brien RJ, Wong PC. Amyloid precursor protein 
processing and Alzheimer’s disease. Annu Rev Neu-
rosci 2011; 34:185–204. DOI:10.1146/annurev-neu-
ro-061010-113613
54. Tamayev R, Zhou D, D’Adamio L. The interactome of the 
amyloid beta precursor protein family members is shaped 
by phosphorylation of their intracellular domains. Mol 
Neurodegener (2009) 4:28. DOI:10.1186/1750-1326-4-
28
55. Lee M-S, Kao S-C, Lemere CA, Xia W, Tseng H-C, Zhou 
Y, et al. APP processing is regulated by cytoplasmic phos-
phorylation. J Cell Biol 2003; 163:83–95. DOI:10.1083/
jcb.200301115
56. Chang K-A, Kim H-S, Ha T-Y, Ha J-W, Shin KY, Jeong 
YH, et al. Phosphorylation of amyloid precursor protein 
(APP) at Thr668 regulates the nuclear translocation of 
the APP intracellular domain and induces neurodegenera-
tion. Mol Cell Biol 2006; 26:4327–4338. DOI:10.1128/
MCB.02393-05
57. Bloom GS. Amyloid-beta and tau: the trigger and bullet 
in Alzheimer disease pathogenesis. JAMA Neurol 2014; 
71:505–508. DOI:10.1001/jamaneurol.2013.5847
58. Ribe EM, Perez M, Puig B, Gich I, Lim F, Cuadrado M, 
et al
degeneration and neuronal loss in double mutant APP/
tau transgenic mice. Neurobiol Dis 2005; 20:814–822. 
DOI:10.1016/j.nbd.2005.05.027
59. Amadoro G, Corsetti V, Ciotti MT, Florenzano F, Capsoni 
S, Amato G,  et al. Endogenous Abeta causes cell death via 
early tau hyperphosphorylation. Neurobiol Aging 2011; 
32:969–990. DOI:10.1016/j.neurobiolaging.2009.06.005
60. Carter C. Alzheimer’s disease: APP, gamma secretase, 
APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, 
CD33, EPHA1, and MS4A2, and their relationships with 
herpes simplex, C. Pneumoniae, other suspect pathogens, 
and the immune system. Int J Alzheimers Dis 2011; 
2011:501862. DOI:10.4061/2011/501862
61. Corsetti V, Amadoro G, Gentile A, Capsoni S, Ciotti MT, 
Cencioni MT, et al
terminal tau fragment in cellular and animal Alzheimer’s 
disease models. Mol Cell Neurosci 2008; 38:381–392. 
DOI:10.1016/j.mcn.2008.03.011
62. Galvez-Contreras AY, Campos-Ordonez T, Lopez-Virgen 
V, Gomez-Plascencia J, Ramos-Zuniga R, et al. Growth 
factors as clinical biomarkers of prognosis and diagnosis 
in psychiatric disorders. Cytokine Growth Factor Rev 
2016; 32:85–96. DOI:10.1016/j.cytogfr.2016.08.004
63. Dell’Omo G, Fiore M, Alleva E. Strain differences in 
mouse response to odours of predators. Behav Processes 
1994; 32:105–115. DOI:10.1016/0376-6357(94)90069-8
64. Weinstock M. Prenatal stressors in rodents: Effects on 
behavior. Neurobiol Stress 2017; 6:3–13. DOI:10.1016/j.
ynstr.2016.08.004
65. Weinstock M. Alterations induced by gestational stress 
in brain morphology and behaviour of the offspring. 
Prog Neurobiol 2001; 65:427–451. DOI:10.1016/S0301-
0082(01)00018-1
66. Maccari S, Darnaudery M, Morley-Fletcher S, Zuena AR, 
Cinque C, Van Reeth O. Prenatal stress and long-term 
consequences: Implications of glucocorticoid hormones. 
Neurosci Biobehav Rev 2003; 27:119–127. DOI:10.1016/
S0149-7634(03)00014-9
67. Pike IL. Maternal stress and fetal responses: evolutionary 
perspectives on preterm delivery. Am J Hum Biol 2005; 
17:55–65. DOI:10.1002/ajhb.20093
68. Oyola MG, Handa RJ. Hypothalamic-pituitary-adrenal 
and hypothalamic-pituitary-gonadal axes: sex differ-
ences in regulation of stress responsivity. Stress 2017; 
20:476–494. DOI:10.1080/10253890.2017.1369523
69. Gaffey AE, Bergeman CS, Clark LA, Wirth MM. Ag-
ing and the HPA axis: Stress and resilience in older 
adults. Neurosci Biobehav Rev 2016; 68:928–945. 
DOI:10.1016/j.neubiorev.2016.05.036
70. Juruena MF. Early-life stress and HPA axis trigger 
recurrent adulthood depression. Epilepsy Behav 2014; 
38:148–159. DOI:10.1016/j.yebeh.2013.10.020
11
Biomed Rev 29, 2018
Nerve growth factor in brain diseases 
71. Guest MA, Its AR, Lin CS. Isomonodromy aspects of the 
tt equations of cecotti and vafa I. Stokes Data. Int Math 
Res Not 2015; 2015:11745–11784. DOI:10.1093/imrn/
rnu250
72. Hua JY, Smith SJ. Neural activity and the dynamics of 
central nervous system development. Nat Neurosci 2004; 
7:327–332. DOI:10.1038/nn1218
73. Branchi I, D’Andrea I, Sietzema J, Fiore M, Di Fausto V, 
Aloe L, et al. Early social enrichment augments adult hip-
pocampal BDNF levels and survival of BRDU-positive 
cells while increasing anxiety- and “depression”-like 
behavior. J Neurosci Res 2006; DOI:10.1002/jnr.20789
74. Branchi I, D’Andrea I, Fiore M, Di Fausto V, Aloe L, 
Alleva E. Early social enrichment shapes social behavior 
and nerve growth factor and brain-derived neurotrophic 
factor levels in the adult mouse brain. Biol Psychiatry 
2006; DOI:10.1016/j.biopsych.2006.01.005
75. Fiore M, Moroni R, Aloe L. Removal of the submaxil-
lary salivary glands and infection with the trematode 
Schistosoma mansoni alters exploratory behavior and 
pain thresholds in female mice. Physiol Behav 1997; 
62:399–406. DOI:10.1016/S0031-9384(97)00036-X
76. Aloe L, Fiore M. Submandibular glands, nerve growth 
Bi-
omed Rev 1998; 9:93–99. DOI:10.14748/bmr.v9.139
77. Fiore M, Amendola T, Triaca V, Alleva E, Aloe L. Fight-
ing in the aged male mouse increases the expression of 
TrkA and TrkB in the subventricular zone and in the 
hippocampus. Behav Brain Res 2005; DOI:10.1016/j.
bbr.2004.08.024
78. Maestripieri D, De Simone R, Aloe L, Alleva E. Social 
status and nerve growth factor serum levels after agonistic 
encounters in mice. Physiol Behav 1990; 47:161–164. 
DOI:10.1016/0031-9384(90)90056-A
79. Bigi S, Maestripieri D, Aloe L, Alleva E. NGF decreases 
isolation-induced aggressive behavior, while increasing 
adrenal volume, in adult male mice. Physiol Behav 1992; 
51:337–343. DOI:10.1016/0031-9384(92)90150-Z
80. Fiore M, Amendola T, Triaca V, Tirassa P, Alleva E, Aloe 
L. Agonistic encounters in aged male mouse potentiate the 
expression of endogenous brain NGF and BDNF: Possi-
ble implication for brain progenitor cells’ activation. Eur 
J Neurosci 2003; 17:1455-1464. DOI: 10.1046/j.1460-
9568.2003.02573.x
81. Aloe L, Alleva E, Fiore M. Stress and nerve growth fac-
tor: Findings in animal models and humans. Pharmacol 
Biochem Behav 2002; 73:159-166. DOI: 10.1016/S0091-
3057(02)00757-8
82. Spillantini MG, Aloe L, Alleva E, De Simone R, Goedert 
M, Levi-Montalcini R. Nerve Growth-Factor Messenger-
RNA and Protein Increase in Hypothalamus in A Mouse 
Model of Aggression. Proc Natl Acad Sci USA 1989; 
86:8555–8559. DOI:10.1073/pnas.86.21.8555
83. Bersani G, Iannitelli A, Fiore M, Angelucci F, Aloe L. 
Data and hypotheses on the role of nerve growth fac-
tor and other neurotrophins in psychiatric disorders. 
Med Hypotheses 2000; 55:199–207. DOI:10.1054/
mehy.1999.1044
84. Stampachiacchiere B, Marinova T, Velikova K, Philipov 
S, Stankulov IS, Chaldakov GN, et al. Altered levels of 
nerve growth factor in the thymus of subjects with my-
asthenia gravis. J Neuroimmunol 2004; 146:199–202. 
DOI:10.1016/j.jneuroim.2003.10.048
85. Fiore M, Angelucci F, Aloe L, Iannitelli A, Korf J. Nerve 
growth factor and brain-derived neurotrophic factor in 
schizophrenia and depression: Findings in humans, and 
animal models. Curr Neuropharmacol 2003; 1:109–123. 
DOI:10.2174/1570159033477206
86. Aloe L, Iannitelli A, Bersani G, Alleva E, Angelucci F, 
Maselli P, et al. Haloperidol administration in humans 
lowers plasma nerve growth factor level: Evidence that 
sedation induces opposite effects to arousal. Neuropsy-
chobiology 1997; 36:65–68. DOI:10.1159/000119364
87. Parikh V, Khan MM, Terry A, Mahadik SP. Differ-
ential effects of typical and atypical antipsychotics 
on nerve growth factor and choline acetyltransferase 
expression in the cortex and nucleus basalis of rats. J 
Psychiatr Res 2004; 38:521–529. DOI:10.1016/j.jpsy-
chires.2004.03.008
88. Ciafrè S, Fiore M, Ceccanti M, Messina MP, Tirassa P, 
Carito V. Role of neuropeptide tyrosine (NPY) in ethanol 
addiction. Biomed Rev 2016; 27:27–39. DOI:10.14748/
bmr.v27.2110
89. Raedler TJ, Knable MB, Weinberger DR. Schizophrenia 
as a developmental disorder of the cerebral cortex. Curr 
Opin Neurobiol 1998; 8:157–161. DOI:10.1016/S0959-
4388(98)80019-6
90. Fiore M, Dell’Omo G, Alleva E, Lipp HP. A comparison 
of behavioural effects of prenatally administered oxaz-
and the real world. Psychopharmacology (Berl) 1995; 
122:72–77. DOI:10.1007/BF02246444
12
Biomed Rev 29, 2018
Ciafrè et al
91. Alleva E, Francia N. Psychiatric vulnerability: sugges-
tions from animal models and role of neurotrophins. Neu-
rosci Biobehav Rev 2009; 33:525–536. DOI:10.1016/j.
neubiorev.2008.09.004
92. Matsuzaki S, Tohyama M. Molecular mechanism of 
schizophrenia with reference to disrupted-in-schizo-
phrenia 1 (DISC1). Neurochem Int 2007; 51:165–172. 
DOI:10.1016/j.neuint.2007.06.018
93. Mackie S, Millar JK, Porteous DJ. Role of DISC1 in neu-
ral development and schizophrenia. Curr Opin Neurobiol 
2007; 17:95–102. DOI:10.1016/j.conb.2007.01.007
94. Millar JK, James K, Brandon NJ, Thomson PA. DISC1 
and DISC2: Discovering and dissecting molecular mecha-
nisms underlying psychiatric illness. Ann Med 2004; 
36:367–378. DOI:10.1080/07853890410033603
95. Tomoda T, Hikida T, Sakurai T. Role of DISC1 in neu-
manifestation and neurotherapeutics. Neurotherapeutics 
2017; 14:623–629. DOI:10.1007/s13311-017-0556-5
96. Dahoun T, Trossbach S V, Brandon NJ, Korth C, 
Howes OD. The impact of Disrupted-in-Schizophrenia 
1 (DISC1) on the dopaminergic system: a  systematic 
review. Transl Psychiatry 2017; 7:e1015. DOI:10.1038/
tp.2016.282
97. Devine MJ, Norkett R, Kittler JT. DISC1 is a coordinator 
-
ment and connectivity. J Physiol 2016; 594:5459–5469. 
DOI:10.1113/JP272187
98. Iwabuchi SJ, Peng D, Fang Y, Jiang K, Liddle EB, Liddle 
PF, et al. Alterations in effective connectivity anchored on 
the insula in major depressive  disorder. Eur Neuropsy-
chopharmacol 2014; 24:1784–1792. DOI:10.1016/j.
euroneuro.2014.08.005
99. Tanti A, Belzung C. Neurogenesis along the septo-tempo-
ral axis of the hippocampus: are depression and the action 
Neuroscience 2013; 
252:234–252. DOI:10.1016/j.neuroscience.2013.08.017
100. Lang UE, Borgwardt S. Molecular mechanisms of depres-
sion: perspectives on new treatment strategies. Cell Phys-
iol Biochem 2013; 31:761–777. DOI:10.1159/000350094
101. Wiener CD, de Mello Ferreira S, Pedrotti Moreira F, Bit-
tencourt G, de Oliveira JF, Lopez Molina M, et al. Serum 
levels of nerve growth factor (NGF) in patients with major 
depression disorder and suicide risk. J Affect Disord 2015; 
184:245–248. DOI:10.1016/j.jad.2015.05.067
102. Banerjee R, Ghosh AK, Ghosh B, Bhattacharyya S, 
Mondal AC. Decreased mRNA and protein expression 
of BDNF, NGF, and their receptors in the hippocampus 
from suicide: An analysis in human postmortem brain. 
Clin Med Insights Pathol 2013; 6:1–11. DOI:10.4137/
CMPath.S12530
103. Mandolesi G, Bullitta S, Fresegna D, Gentile A, De Vito 
F, Dolcetti E, et al. Interferon-gamma causes mood abnor-
malities by altering cannabinoid CB1 receptor function 
in the mouse striatum. Neurobiol Dis 2017; 108:45–53. 
DOI:10.1016/j.nbd.2017.07.019
104. Campos AC, Vaz GN, Saito VM, Teixeira AL. Further 
evidence for the role of interferon-gamma on anxiety- and 
depressive-like behaviors: involvement of hippocampal 
neurogenesis and NGF production. Neurosci Lett 2014; 
578:100–105. DOI:10.1016/j.neulet.2014.06.039
105. McGeary JE, Gurel V, Knopik VS, Spaulding J, McMi-
brain. Neuropeptides 2011; 45:317–322. DOI:10.1016/j.
npep.2011.06.002
106. Taurines R, Schwenck C, Westerwald E, Sachse M, 
Siniatchkin M, Freitag C. ADHD and autism: differential 
diagnosis or overlapping traits? A selective review. Atten 
 2012; 4:115–139. DOI:10.1007/
s12402-012-0086-2
107. Khanzada NS, Butler MG, Manzardo AM. Gene analytics 
pathway: Analysis and genetic overlap among Autism 
Spectrum Disorder, Bipolar Disorder and Schizophrenia. 
Int J Mol Sci 2017; 18: DOI:10.3390/ijms18030527
108. Stamova BS, Tian Y, Nordahl CW, Shen MD, Rogers S, 
Amaral DG, et al. Evidence for differential alternative 
splicing in blood of young boys with autism spectrum 
disorders. Mol Autism 2013; 4:30. DOI:10.1186/2040-
2392-4-30
109. Lu AT-H, Yoon J, Geschwind DH, Cantor RM. QTL 
replication and targeted association highlight the nerve 
-
cits in autism spectrum disorders. Mol Psychiatry 2013; 
18:226–235. DOI:10.1038/mp.2011.155
110. Ceccanti M, Inghilleri M, Attilia ML, Raccah R, Fiore 
M, Zangen A, et al. Deep TMS on alcoholics: effects 
on cortisolemia and dopamine pathway modulation. A 
pilot study. Can J Physiol Pharmacol 2015; 93:283–290. 
DOI:10.1139/cjpp-2014-0188
111. Ciafrè S, Carito V, Tirassa P, Ferraguti G, Attilia ML, 
Ciolli P, et al. Ethanol consumption and innate neuroim-
munity. Biomed Rev 2017; 28:49–61. DOI:10.14748/bmr.
v28.4451
13
Biomed Rev 29, 2018
Nerve growth factor in brain diseases 
112. Ciafrè S, Carito V, Ferraguti G, Greco A, Chaldakov 
GN, Fiore M, Ceccanti M. How alcohol drinking af-
fects our genes: an epigenetic point of view. Biochem 
Cell Biol 2018; bcb-2018-0248. DOI:10.1139/bcb-
2018-0248
113. Ledda R, Battagliese G, Attilia F, Rotondo C, Pisciotta 
F, Gencarelli S, et al. Drop-out, relapse and abstinence 
Physiol Behav 2019; 198:67–75. DOI:10.1016/j.phys-
beh.2018.10.009
114. Ceccanti M, Iannitelli A, Fiore M. Italian Guidelines 
for the treatment of alcohol dependence. Riv Psichiatr 
2018; 53:105–106. DOI:10.1708/2925.29410
115. Ceccanti M, Coriale G, Hamilton DA, Carito V, Coc-
curello R, Scalese B, et al. Virtual Morris task responses 
in individuals in an abstinence phase from alcohol. Can 
J Physiol Pharmacol 2018; 96:128–136. DOI:10.1139/
cjpp-2017-0013
116. Ceccanti M, Hamilton D, Coriale G, Carito V, Aloe 
L, Chaldakov G,  et al. Spatial learning in men un-
Physiol Behav 2015; 
149:324–330. DOI:10.1016/j.physbeh.2015.06.034
117. Fein G, Torres J, Price LJ, Di Sclafani V. Cognitive 
performance in long-term abstinent alcoholic indi-
viduals. Alcohol Clin Exp Res 2006; 30:1538–1544. 
DOI:10.1111/j.1530-0277.2006.00185.x
118. Bernardin F, Maheut-Bosser A, Paille F. Cognitive 
impairments in alcohol-dependent subjects. Front Psy-
chiatry 2014; 5:78. DOI:10.3389/fpsyt.2014.00078
119. Green CR, Mihic AM, Nikkel SM, Stade BC, Rasmus-
sen C, Munoz DP, et al
in children with fetal alcohol spectrum disorders 
(FASD) measured using the Cambridge Neuropsycho-
logical Tests Automated Battery (CANTAB). J Child 
Psychol Psychiatry Allied Discip 2009; 50:688–697. 
DOI:10.1111/j.1469-7610.2008.01990.x
120. Ferraguti G, Ciolli P, Carito V, Battagliese G, Man-
cinelli R, Ciafrè S, et al. Ethylglucuronide in the urine 
as a marker of alcohol consumption during pregnancy: 
Comparison with four alcohol screening question-
naires. Toxicol Lett 2017; 275:49–56. DOI:10.1016/j.
toxlet.2017.04.016
121. Sakata-Haga H, Fukui Y. Effects of ethanol on the 
development of circadian time keeping system. Nihon 
Arukoru Yakubutsu Igakkai Zasshi 2007; 42:67–75.
122. del Campo M, Jones KL. A review of the physi-
cal features of the fetal alcohol spectrum disorders. 
Eur J Med Genet 2017; 60:55–64. DOI:10.1016/j.
ejmg.2016.10.004
123. Kodituwakku P, Coriale G, Fiorentino D, Aragón AS, 
Kalberg WO, Buckley D, et al. Neurobehavioral charac-
teristics of children with fetal alcohol spectrum disorders 
in communities from Italy: Preliminary results. Alcohol 
Clin Exp Res 2006;30:1551–1561. DOI:10.1111/j.1530-
0277.2006.00187.x
124. Aloe L, Tuveri MA, Guerra G, Pinna L, Tirassa P, 
Micera A, et al. Changes in human plasma nerve 
growth factor level after chronic alcohol consumption 
and withdrawal. Alcohol Exp Res 1996; 20:462–465. 
DOI:10.1111/j.1530-0277.1996.tb01076.x
125. Carito V, Ceccanti M, Cestari V, Natella F, Bello C, 
Coccurello R,  et al. Olive polyphenol effects in a mouse 
model of chronic ethanol addiction. Nutrition 2017; 
33:65–69. DOI:10.1016/j.nut.2016.08.014
126. Carito V, Ceccanti M, Tarani L, Ferraguti G, N. Chaldak-
ov G, Fiore M. Neurotrophins’ modulation by olive poly-
phenols. Curr Med Chem 2016; 23:3189–3197. DOI: 
10.2174/0929867323666160627104022
127. Carito V, Ceccanti M, Chaldakov G, Tarani L, De 
Nicolò S, Ciafrè S, et al. Polyphenols, nerve growth 
factor, brain-derived neurotrophic factor, and the brain. 
In: Bioactive Nutraceuticals and Dietary Supplements 
in Neurological and Brain Disease: Prevention and 
Therapy 2016; 65–71. DOI:10.1016/B978-0-12-
411462-3.00007-2
128. De Nicolò S, Carito V, Fiore M, Laviola G. Aberrant 
to ethanol or red wine early in development. Curr Dev 
Disord Reports 2014; 1:173–180. DOI:10.1007/s40474-
014-0023-5
129. Fiore M, Mancinelli R, Aloe L, Laviola G, Sornelli 
F, Vitali M,  et al. Hepatocyte growth factor, vascular 
endothelial growth factor, glial cell-derived neuro-
trophic factor and nerve growth factor are differentially 
affected by early chronic ethanol or red wine intake. 
Toxicol Lett 2009; 188:208–213. DOI:10.1016/j.tox-
let.2009.04.013
130. Ceccanti M, Mancinelli R, Tirassa P, Laviola G, Rossi 
S, Romeo M,  et al. Early exposure to ethanol or red 
wine and long-lasting effects in aged mice. A study on 
nerve growth factor, brain-derived neurotrophic fac-
tor, hepatocyte growth factor, and vascular endothelial 
growth factor. Neurobiol Aging 2012; 33:359–367. 
DOI:10.1016/j.neurobiolaging.2010.03.005
14
Biomed Rev 29, 2018
Ciafrè et al
131. Fiore M, Laviola G, Aloe L, di Fausto V, Mancinelli R, 
Ceccanti M. Early exposure to ethanol but not red wine 
at the same alcohol concentration induces behavioral 
and brain neurotrophin alterations in young and adult 
mice. Neurotoxicology 2009; 30:59–71. DOI:10.1016/j.
neuro.2008.11.009
132. Ceccanti M, De Nicolò S, Mancinelli R, Chaldakov G, 
Carito V, Ceccanti M, et al. NGF and BDNF long-term 
variations in the thyroid, testis and adrenal glands of a 
mouse model of fetal alcohol spectrum disorders. Ann Ist 
Super Sanita 2013; 49:383–390. DOI:10.4415/ANN-13-
04-11
133. Carito V, Ceccanti M, Ferraguti G, Coccurello R, Ciafrè 
S, Tirassa P,  et al. NGF and BDNF alterations by prenatal 
alcohol exposure. Curr Neuropharmacol 2017; 15: DOI:
10.2174/1570159X15666170825101308
-
tion on brain nerve growth factor and its target cells in 
developing and adult rodents. Ann Ist Super Sanita 1993; 
29:179–183.
135. Angelucci F, Fiore M, Cozzari C, Aloe L. Prenatal ethanol 
effects on NGF level, NPY and ChAT immunoreactiv-
ity in mouse entorhinal cortex: A preliminary study. 
Neurotoxicol Teratol 1999; 21:415–425. DOI:10.1016/
S0892-0362(99)00005-7
136. Aloe L, Tirassa P. The effect of long-term alcohol intake 
on brain NGF target cells of aged rats. Alcohol 1992; 
9:299–304. DOI:10.1016/0741-8329(92)90070-q
137. Lhullier AC, Moreira FP, da Silva RA, Marques MB, 
Bittencourt G, Pinheiro RT, et al. Increased Serum Neu-
rotrophin Levels Related to Alcohol Use Disorder in a 
Young Population Sample. Alcohol Clin Exp Res 2015; 
39:30–35. DOI:10.1111/acer.12592
138. Ceccanti M, Coccurello R, Carito V, Ciafrè S, Ferraguti 
G, Giacovazzo G, et al. Paternal alcohol exposure in 
mice alters brain NGF and BDNF and increases ethanol-
elicited preference in male offspring. Addict Biol 2016; 
21:776–787. DOI:10.1111/adb.12255
139. Miller MW, Mooney SM. Chronic exposure to ethanol 
alters neurotrophin content in the basal forebrain-
cortex system in the mature rat: Effects on autocrine-
paracrine mechanisms. J Neurobiol 2004; 60:490–498. 
DOI:10.1002/neu.20059
140. Mooney SM, Miller MW. Nerve growth factor neu-
roprotection of ethanol-induced neuronal death in rat 
cerebral cortex is age dependent. Neuroscience 2007; 
149:372–381.
141. Li Z, Ding M, Thiele CJ, Luo J. Ethanol inhibits brain-
derived neurotrophic factor-mediated intracellular 
signaling and activator protein-1 activation in cerebel-
lar granule neurons. Neuroscience 2004; 126:149–162. 
DOI:10.1016/j.neuroscience.2004.03.028
142. Aloe L, Fiore M. TNF-alpha expressed in the brain 
of transgenic mice lowers central tyroxine hydroxy-
lase immunoreactivity and alters grooming behavior. 
Neurosci Lett 1997; 238:65–68. DOI:10.1016/S0304-
3940(97)00850-1
143. Heberlein A, Schuster R, Kleimann A, Groh A, Kordon A, 
Opfermann B, et al. Joint effects of the epigenetic altera-
tion of neurotrophins and cytokine signaling: A possible 
exploratory model of affective symptoms in alcohol-
dependent patients? Alcohol Alcohol 2017; 52:277–281. 
DOI:10.1093/alcalc/agw100
144. Rassi AJ, Rassi A, Marcondes de Rezende J. Ameri-
can trypanosomiasis (Chagas disease). Infect Dis 
Clin North Am 2012; 26:275–291. DOI:10.1016/j.
idc.2012.03.002
145. Rassi AJ, Rassi A, Marin-Neto JA. Chagas disease. Lancet 
(London, England) 2010; 375:1388–1402. DOI:10.1016/
S0140-6736(10)60061-X
146. Holmes PH, Miles MA. The trypanosomiases. CAB Int 
Wallingford, UK 2004.
147. Sofroniew M V, Howe CL, Mobley WC. Nerve Growth 
Factor Signaling, Neuroprotection, and Neural Repair. 
Annu Rev Neurosci 2001; 24:1217–1281. DOI:10.1146/
annurev.neuro.24.1.1217
148. Chuenkova M V., Pereira MA. The T. cruzi trans-
sialidase induces PC12 cell differentiation via MAPK/
ERK pathway. Neuroreport 2001; 12:3715–3718. 
DOI:10.1097/00001756-200112040-00022
149. Hoff R, Teixeira RS, Carvalho JS, Mott KE. Trypanosoma 
of Chagas’ disease. N Engl J Med 1978; 298:604–606. 
DOI:10.1056/NEJM197803162981106
150. De Souza MM, Andrade SG, Barbosa AA, Santos 
RTM, Alves VAF, Andrade ZA. Trypanosoma cruzi 
strains and autonomic nervous system pathology in 
experimental Chagas disease. Mem Inst Oswaldo 
Cruz  1996; 91:217–224. DOI:10.1590/S0074-
02761996000200018
151. Tafuri WL. Pathogenesis of lesions of the autonomic nerv-
ous system of the mouse in experimental acute Chagas’ 
15
Biomed Rev 29, 2018
Nerve growth factor in brain diseases 
disease. Light and electron microscope studies. Am J Trop 
Med Hyg 1970; 19:405–417.
152. Molina HA, Cardoni RL, Rimoldi MT. The neuro-
muscular pathology of experimental Chagas’ disease. 
J Neurol Sci 1987; 81:287–300. DOI:10.1016/0022-
510X(87)90104-3
153. Said G, Joskowicz M, Barreira AA, Eisen H. Neuropathy 
associated with experimental Chagas’ disease. Ann Neurol 
1985; 18:676–683. DOI:10.1002/ana.410180609
154. Bocchi EA, Bestetti RB, Scanavacca MI, Cunha Neto E, 
Issa VS. Chronic Chagas heart disease management: From 
etiology to cardiomyopathy treatment. J Am Coll Cardiol 
2017; 70:1510–1524. DOI:10.1016/j.jacc.2017.08.004
155. Malik LH, Singh GD, Amsterdam EA. Chagas heart 
disease: An update. Am J Med 2015; 128:1251.e7-9. 
DOI:10.1016/j.amjmed.2015.04.036
156. Chuenkova M V, Pereiraperrin M. Neurodegeneration 
and neuroregeneration in Chagas disease. Adv Parasitol 
2011; 76:195–233. DOI:10.1016/B978-0-12-385895-
5.00009-8
157. Chuenkova M V, PereiraPerrin M. Chagas’ disease para-
site promotes neuron survival and differentiation through 
TrkA nerve growth factor receptor. J Neurochem 2004; 
91:385–394. DOI:10.1111/j.1471-4159.2004.02724.x
158. Palin MS, Mathew R, Towns G. Spinal neuroschistoso-
miasis. Br J Neurosurg 2015; 29:582–584. DOI:10.310
9/02688697.2015.1016890
159. Carod-Artal FJ. Neuroschistosomiasis. Expert Rev Anti 
Infect Ther 2010; 8:1307–1318. DOI:10.1586/eri.10.111
160. Ferrari TCA, Gazzinelli G, Correa-Oliveira R. Immune 
response and pathogenesis of neuroschistosomiasis 
mansoni. Acta Trop 2008; 108:83–88. DOI:10.1016/j.
actatropica.2008.02.010
161. Nascimento-Carvalho CM, Moreno-Carvalho OA. 
Neuroschistosomiasis due to Schistosoma mansoni: a 
review of pathogenesis, clinical syndromes and diag-
nostic approaches. Rev Inst Med Trop Sao Paulo 2005; 
47:179–184. DOI:S0036-46652005000400001
162. Pittella JEH. Neuroschistosomiasis. Brain Pathol 1997; 
7:649–662. DOI:10.1111/j.1750-3639.1997.tb01080.x
163. Varilek GW, Weinstock J V., Pantazis NJ. Isolated he-
patic granulomas from mice infected with Schistosoma 
mansoni contain nerve growth factor. Infect Immun 1991; 
59:4443–4449.
164. Aloe L, Moroni R, Mollinari C, Tirassa P. Schistosoma 
mansoni infection enhances the levels of NGF in the liver 
and hypothalamus of mice. Neuroreport 1994; 5:1030–
1032. DOI:10.1097/00001756-199405000-00003
165. Aloe L, Moroni R, Fiore M, Angelucci F. Chronic parasite 
infection in mice induces brain granulomas and differen-
tially alters brain nerve growth factor levels and thermal 
responses in paws. Acta Neuropathol 1996; 92:300–305. 
DOI:10.1007/s004010050522
but not NGF in murine hyperalgesia induced by parasitic 
infection. Psychopharmacology (Berl) 1997; 134:287–
292. DOI:10.1007/s002130050451
167. Fiore M, Carere C, Moroni R, Aloe L. Passive avoidance 
response in mice infected with Schistosoma mansoni. 
Physiol Behav 2002;75:449–454. DOI:10.1016/S0031-
9384(01)00661-8
Schistosoma mansoni infection in the mouse. Arch 
Physiol Biochem 2001; 109:361–364. DOI:10.1076/
apab.109.4.361.4247
169. Fiore M, Moroni R, Alleva E, Aloe L. Schistosoma 
mansoni Exp 
Parasitol 1996; 83:46–54. DOI:10.1006/expr.1996.0047
Schistosoma mansoni infection: New information from 
the mouse model. Parasitol Today 1998; 14:314–318. 
DOI:10.1016/S0169-4758(98)01283-6
171. Fiore M, Alleva E, Moroni R, Aloe L. Infection with 
Schistosoma mansoni in mice induces changes in noci-
ception and exploratory behavior. Physiol Behav 1998; 
65:347–353. DOI:10.1016/S0031-9384(98)00171-1
172. Tuszynski MH, Blesch A. Nerve growth factor: from ani-
mal models of cholinergic neuronal degeneration to gene 
therapy in Alzheimer’s disease. Prog Brain Res 2004; 
146:441–449. DOI:10.1016/S0079-6123(03)46028-7
173. Tuszynski MH, Thal L, Pay M, Salmon DP, Sang UH, 
Bakay R, et al. A phase 1 clinical trial of nerve growth 
factor gene therapy for Alzheimer disease. Nat Med 2005; 
11:551–555. DOI:10.1038/nm1239
174. Malkki H. Alzheimer disease: NGF gene therapy activates 
neurons in the AD patient brain. Nat Rev Neurol 2015; 
11:548. DOI:10.1038/nrneurol.2015.170
175. Karami A, Eyjolfsdottir H, Vijayaraghavan S, Lind G, 
Almqvist P, Kadir A, et al. Changes in CSF cholinergic 
biomarkers in response to cell therapy with NGF in 
patients with Alzheimer’s disease. Alzheimers Dement 
2015; 11:1316–1328. DOI:10.1016/j.jalz.2014.11.008
16
Biomed Rev 29, 2018
Ciafrè et al
176. Tuszynski MH, Yang JH, Barba D, Hoi-Sang U, Bakay 
RAE, Pay MM, et al. Nerve growth factor gene therapy 
activation of neuronal responses in Alzheimer disease. 
JAMA Neurol 2015; 72:1139–1147. DOI:10.1001/jama-
neurol.2015.1807
177. Parikh V, Evans DR, Khan MM, Mahadik SP. Nerve 
and medicated chronic schizophrenic patients: Possible 
implications for treatment outcome. Schizophr Res 2003; 
60:117–123. DOI:10.1016/S0920-9964(02)00434-6
178. Machado-Vieira R, Manji HK, Zarate CAJ. The role 
of lithium in the treatment of bipolar disorder: conver-
gent evidence for neurotrophic effects as a unifying 
hypothesis. Bipolar Disord 2009; 11 (Suppl 2):92–109. 
DOI:10.1111/j.1399-5618.2009.00714.x
179. Gorbachevskaya N, Bashina V, Gratchev V, Iznak A. 
Cerebrolysin therapy in Rett syndrome: Clinical and EEG 
mapping study. Brain Dev 2001 23:S90-93. DOI:10.1016/
S0387-7604(01)00349-7
G, Tunçel N,  et al. Triactome: Neuro-immune-adipose 
interactions. Implication in vascular biology. Front Im-
munol
181 Chaldakov GN, Aloe  A, Hiriart M, Fiore M, Zhelezov 
M. Cognitive adiposcience: A gold mine to be unfolded. 
Adipobiology 2018; 10:75-79.
